Comparative Pharmacology
Head-to-head clinical analysis: BAYCOL versus ROSUVASTATIN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYCOL versus ROSUVASTATIN CALCIUM.
BAYCOL vs ROSUVASTATIN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, upregulates LDL receptors, and enhances clearance of LDL from plasma.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
Oral, 5-40 mg once daily, starting at 5-10 mg, titrated based on LDL-C response, maximum 40 mg/day.
None Documented
None Documented
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
Terminal elimination half-life is approximately 19 hours, which supports once-daily dosing and allows for sustained HMG-CoA reductase inhibition.
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Approximately 90% of the absorbed dose is excreted in feces via biliary elimination, with the remaining 10% excreted renally as unchanged drug and metabolites. Unchanged rosuvastatin accounts for about 5% of the dose in urine.
Category C
Category D/X
Statin
Statin